MedElevator Войти в исследования
← Поиск публикаций
Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2002

Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia.

Singletary S Eva, Atkinson Edward N, Hoque Ashraful, Sneige Nour, Sahin Ayse A, Fritsche Herbert A, Lotan Reuben, Lu Tao, Hittelman Walter N, Bevers Therese B, Stelling Carol B, Lippman Scott M

Клиническое исследованиеКлиническое исследование II фазыСравнительное исследованиеКонтролируемое клиническое исследованиеСтатьяПоддержка службы здравоохранения СШАПеревод пока не подготовлен

Аннотация

PURPOSE: Surrogate end point biomarkers (SEBs) that can be measured in ductal carcinoma in situ or early-stage invasive cancer are needed to improve the efficiency and reduce the cost of chemoprevention trials.

EXPERIMENTAL

DESIGN

We conducted a prospective study to develop SEBs for tamoxifen and N-[4-hydroxyphenyl]retinamide by administering either a placebo or both drugs for 2-4 weeks to women with ductal carcinoma in situ or early invasive cancers in the interval between the initial diagnostic core biopsy and definitive surgery. The major statistical end point of the study was pre- versus posttreatment change in cell proliferation, as measured by changes in Ki67 labeling indices. In addition, estrogen receptor (ER), HER2/neu, p53, retinoid receptors, and DNA index were measured.

RESULTS

Between February 1997 and April 200, 52 patients were registered on the study, and 36 (20 in the placebo arm and 16 in the treatment arm) were available for analysis. No statistically significant pre- versus posttreatment differences in Ki67 labeling index or in the other markers were observed in the treatment arm compared with the placebo arm. There was a trend toward increased treatment response in ER-positive versus ER-negative patients, but this could not be rigorously analyzed because of the low sample size and the unequal distribution of ER-positive patients in the two study arms.

CONCLUSION

Future SEB trials for breast carcinoma must (a) incorporate information about patient hormonal status into the study design and (b) resolve problems in patient accrual.

Для цитирования: Singletary S Eva, Atkinson Edward N, Hoque Ashraful, Sneige Nour, Sahin Ayse A, Fritsche Herbert A, Lotan Reuben, Lu Tao, Hittelman Walter N, Bevers Therese B, Stelling Carol B, Lippman Scott M. Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.